Savicell the Product for diagnosis of lung cancer at early stages

2019: The announcement of the test for early diagnosis of cancer

On June 26, 2019 the Israeli company Savicell reported that it developed the test for early diagnosis of cancer.

According to the company, the product Savicell differs in the fact that it is concentrated on an area research — immuno-metabolism. It changes which undergo cages of the immune system at collision with some factors of diseases.

Cages of the immune system which are modified in this case are not antibodies (cages which make us steady against viruses, which we already faced). They are 'cages murderers'. They are not adapted to a specific disease, but, nevertheless, are exposed to changes which are caused by disease type, and affect capability of cages to cope with the illness.

The technology on which the product Savicell is based was developed in Tel Aviv University by professor Fernando Patolscy, and information on it reached cofounders and brothers Giora and Eyal Davidovits (SOO). To this Gior was a senior manager in Procter and Gamble consumer goods company and in pharmaceutical company Johnson & Johnson, also he directed a diabetic startup. Eyal worked in Intel on projects, the budget and operational planning.

In an interview for Globes answers in what a difference between Savicell and the companies which offer 'a liquid biopsy' – diagnosis of cancer by means of blood test or selections.

The first product which the company develops is intended for diagnosis of lung cancer – like cancer at which early diagnostics is crucial for treatment. At detection of oncology at the first stage the survival is 80%, in comparison with 13-14% if cancer is detected at the third stage.

For June, 2019 the majority diagnosed at the first stage has no symptoms. Patients begin to undergo treatment after accidentally detect cancer in the picture made with other purpose. At detection in the picture of a tumor, there are two options: make a biopsy to define, what is it, or to wait and look whether the tumor sizes will change over time. The biopsy is considered the risky procedure therefore often it is postponed. But happens and so that the invasive analysis is done too late. Therefore alternative diagnostics is extremely necessary.

The product did not get approval of the Food and Drug Administration of the USA (FDA) yet, but in the American market results of laboratory researches can be sold after approval by authorized laboratory. Savicell intends to address to FDA later.

Meanwhile in Israel it was tested which results were published in the Cancer Immunology and Immunotherapy magazine. Testing showed that the level of sensitivity of the test (identification of patients as patients) was 91%, and its specificity (identification of healthy people as healthy) – 80%. These are good results for early diagnostics.^[1]

Notes